-
公开(公告)号：US20240180880A1
公开(公告)日：2024-06-06
申请号：US18454612
申请日：2023-08-23
申请人： Epizyme, Inc.
IPC分类号： A61K31/4184 , A61K31/155 , A61K31/165 , A61K31/167 , A61K31/17 , A61K31/198 , A61K31/4045 , A61K31/407 , A61K31/4192 , A61K31/428 , A61K31/437 , A61K31/4406 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/4965 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/706 , A61K38/46 , A61P7/06 , C07C211/44 , C07C211/45 , C07C211/46 , C07C211/47 , C07C211/48
CPC分类号： A61K31/4184 , A61K31/155 , A61K31/165 , A61K31/167 , A61K31/17 , A61K31/198 , A61K31/4045 , A61K31/407 , A61K31/4192 , A61K31/428 , A61K31/437 , A61K31/4406 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/4965 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/706 , A61K38/465 , A61P7/06 , C07C211/44 , C07C211/45 , C07C211/46 , C07C211/47 , C07C211/48
摘要： The present disclosure relates to a method of preventing or treating a blood disorder (e.g., sickle-cell disease) via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
-
公开(公告)号：US20230364086A1
公开(公告)日：2023-11-16
申请号：US18188691
申请日：2023-03-23
申请人： Epizyme, Inc.
发明人： John Emmerson CAMPBELL , Kenneth William DUNCAN , Maria Alejandra RAIMONDI , Christine KLAUS , Elayne PENEBRE
IPC分类号： A61K31/506 , A61P35/00 , A61K31/203 , A61K31/4375 , A61K31/44 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/706
CPC分类号： A61K31/506 , A61P35/00 , A61K31/203 , A61K31/4375 , A61K31/44 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/706
摘要： The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
-
公开(公告)号：US20210060025A1
公开(公告)日：2021-03-04
申请号：US16644202
申请日：2018-09-05
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61K33/243 , A61K31/337 , A61K31/475 , A61K31/7068 , A61K31/519 , A61K31/53 , A61K31/167 , A61K31/4745 , A61K31/517 , A61K31/506
摘要： The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.
-
公开(公告)号：US20190151325A1
公开(公告)日：2019-05-23
申请号：US16073558
申请日：2017-01-27
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/704 , A61K31/706 , A61K31/506 , A61P35/00 , A61K33/243
摘要： The disclosure relates to a method for treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and a second agent in a therapeutically effective amount. Preferably, the first agent comprises an EZH2 inhibitor, e.g., tazemetostat or a pharmaceutically acceptable salt thereof. In certain embodiments, the methods of the disclosure are used to treat breast cancer, ovarian cancer, or both.
-
公开(公告)号：US20240299352A1
公开(公告)日：2024-09-12
申请号：US18568368
申请日：2022-06-08
申请人： Epizyme, Inc.
发明人： Maria Alejandra RAIMONDI , Jenniffer Anne TOTMAN , Vinny MOTWANI , Katherine Louise COSMOPOULOS , Dorothy BRACH , Daniel T. DRANSFIELD
IPC分类号： A61K31/404 , A61K45/06 , A61P35/00
CPC分类号： A61K31/404 , A61K45/06 , A61P35/00
摘要： The present disclosure provides SETD2 protein inhibitors, and methods, uses, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor and a Second Therapeutic Agent, wherein the Second Therapeutic Agent comprises one or more BTK inhibitors, one or more anti-CD20 monoclonal antibodies, one or more alkylating agents, one or more topoisomerase II inhibitors, one or more vinca alkaloids, one or more platinum-based drugs, one or more nucleoside anticancer agents, one or more PI3K inhibitors, one or more CDK4/6 inhibitors, one or more CARM1 inhibitors, one or more inhibitors of enzymes of DNA damage repair, one or more SYK inhibitors, or one or more MEK inhibitors, or a combination thereof.
-
公开(公告)号：US20240293418A1
公开(公告)日：2024-09-05
申请号：US18411139
申请日：2024-01-12
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61K9/00 , A61K31/167 , A61K31/404 , A61K31/4184 , A61K31/436 , A61K31/437 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/52 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K38/08 , A61K39/395 , A61P35/00
CPC分类号： A61K31/5377 , A61K9/0053 , A61K31/167 , A61K31/404 , A61K31/4184 , A61K31/436 , A61K31/437 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/52 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K38/08 , A61K39/3955 , A61P35/00
摘要： The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. Preferably, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat multiple myeloma or mantle cell lymphoma.
-
公开(公告)号：US20200054635A1
公开(公告)日：2020-02-20
申请号：US16606833
申请日：2018-04-20
申请人： Epizyme, Inc.
发明人： John Emmerson CAMPBELL , Kenneth William DUNCAN , Maria Alejandra RAIMONDI , Christine KLAUS , Elayne PENEBRE
IPC分类号： A61K31/506 , A61K31/203 , A61K31/4375 , A61K31/44 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/706 , A61P35/00
摘要： The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
-
公开(公告)号：US20200030355A1
公开(公告)日：2020-01-30
申请号：US16248925
申请日：2019-01-16
申请人： Epizyme, Inc. , Celgene Corporation
发明人： Christine KLAUS , Maria Alejandra RAIMONDI , Scott Richard DAIGLE , Roy MacFarlane POLLOCK , Vivek CHOPRA
IPC分类号： A61K31/7064 , A61K45/06 , A61K31/706 , A61K31/7068 , A61K31/519 , A61K31/7076 , A61K31/4745 , A61K31/136 , A61K31/704 , A61K31/5377 , A61K31/4045 , A61K31/135 , A61P35/00
摘要： The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20240277721A1
公开(公告)日：2024-08-22
申请号：US18431262
申请日：2024-02-02
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61K31/167 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/7068 , A61K33/243 , A61K45/06
CPC分类号： A61K31/5377 , A61K31/167 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/7068 , A61K33/243 , A61K45/06
摘要： The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.
-
公开(公告)号：US20240041895A1
公开(公告)日：2024-02-08
申请号：US18188721
申请日：2023-03-23
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61P35/00 , A61K31/282 , A61K31/4184 , A61K31/436 , A61K31/4406 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/519 , A61K31/55 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K38/15 , A61N5/10
CPC分类号： A61K31/5377 , A61P35/00 , A61K31/282 , A61K31/4184 , A61K31/436 , A61K31/4406 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/519 , A61K31/55 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K38/15 , A61N5/10
摘要： The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.03 秒)
